The Latest on Ketamine-Based Mental Health Treatments
Recent news on ketamine-based mental health treatments reveals a mix of significant regulatory updates, expanding research, and concerns over efficacy and safety, particularly regarding off-label use.
In January 2025, the FDA expanded the approval for Johnson & Johnson’s esketamine nasal spray to allow it to be used as a standalone monotherapy for adults with treatment-resistant depression (TRD). Previously, it was only approved for use in combination with an oral antidepressant.
Following reports on the risks of at-home administration, regulatory bodies are increasing scrutiny of the hundreds of new, loosely regulated ketamine clinics. The FDA and other organizations caution against using compounded ketamine products for unapproved psychiatric uses, especially without in-person monitoring.
Professional groups like the American Society of Anesthesiologists (ASA) issued new guidance in early 2025. They emphasize that ketamine treatment for mental health should only be prescribed and monitored by trained professionals within a structured, comprehensive treatment plan.
An October 2025 study led by researchers at Mass General Brigham retrospectively compared intravenous (IV) ketamine and intranasal (IN) esketamine for TRD. It found that while both reduced depression severity, IV ketamine was associated with faster and greater improvements in symptoms.
The October 2025 KARMA-Dep 2 trial, published in JAMA Psychiatry, found that repeated IV ketamine infusions offered no statistically significant advantage over an active placebo (midazolam) for hospitalized patients with moderate to severe depression. Researchers suggested that ketamine’s antidepressant effects might be overstated compared to psychoactive placebos.
A February 2024 study of veterans with severe, treatment-resistant depression found that IV ketamine infusions helped many. Some patients required multiple infusions over months to see sustained improvement. The study noted that this population often deals with co-occurring conditions like PTSD and substance use disorders.
A study published in Science in May 2025 provided insights into ketamine’s mechanism of action, finding that it enhances synaptic plasticity and extends antidepressant effects by augmenting ERK activity. Also, a July 2025 University of Florida study suggested that medically supervised ketamine may help patients with PTSD by inducing a “controlled dissociation,” allowing them to process trauma without re-experiencing fear. An October 2023 real-world study showed that IV ketamine infusions reduced symptoms of depression and anxiety in patients with treatment-resistant bipolar depression, with the effects lasting with repeated doses. Clinics are increasingly integrating ketamine therapy with traditional psychotherapy, such as cognitive behavioral therapy (CBT), to help patients maximize the benefits of the drug’s neuroplastic effects.
Despite growing evidence, insurance coverage for ketamine treatments, particularly off-label IV infusions, remains inconsistent. This creates significant affordability barriers for many patients. The high cost of treatment and varying insurance policies mean that many patients must pay thousands of dollars out-of-pocket, limiting access for lower-income individuals.
Always consult a qualified medical professional for personalized advice regarding mental health treatments. Talk to us anytime by writing to us on our website or call (585) 442-6960.
